333 related articles for article (PubMed ID: 16022171)
21. Assessment of futility in clinical trials.
Snapinn S; Chen MG; Jiang Q; Koutsoukos T
Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
[TBL] [Abstract][Full Text] [Related]
22. Group sequential t-test for clinical trials with small sample sizes across stages.
Shao J; Feng H
Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
[TBL] [Abstract][Full Text] [Related]
23. Group sequential and adaptive designs: a novel, promising tool for nursing research.
Baldi I; Gouchon SM; Di Giulio P; Buja A; Gregori D
J Adv Nurs; 2011 Aug; 67(8):1824-33. PubMed ID: 21517937
[TBL] [Abstract][Full Text] [Related]
24. Accounting for interim safety monitoring of an adverse event upon termination of a clinical trial.
Dallas MJ
J Biopharm Stat; 2008; 18(4):631-8; discussion 439-45. PubMed ID: 18607795
[TBL] [Abstract][Full Text] [Related]
25. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
Hung HM; Wang SJ; O'Neill R
J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
[TBL] [Abstract][Full Text] [Related]
26. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials.
Cheng Y; Shen Y
Biometrics; 2004 Dec; 60(4):910-8. PubMed ID: 15606411
[TBL] [Abstract][Full Text] [Related]
27. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
28. The reassessment of trial perspectives from interim data--a critical view.
Bauer P; Koenig F
Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
[TBL] [Abstract][Full Text] [Related]
29. Some optimal and non-optimal two-stage designs using an alpha-spending function.
Patel HI
Stat Med; 1996 Aug; 15(16):1739-45. PubMed ID: 8870156
[TBL] [Abstract][Full Text] [Related]
30. Sample size re-estimation for adaptive sequential design in clinical trials.
Gao P; Ware JH; Mehta C
J Biopharm Stat; 2008; 18(6):1184-96. PubMed ID: 18991116
[TBL] [Abstract][Full Text] [Related]
31. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
Zhao Y; Grambsch PM; Neaton JD
Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
[TBL] [Abstract][Full Text] [Related]
32. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.
Whitehead J; Matsushita T
Stat Med; 2003 Mar; 22(5):677-87. PubMed ID: 12587099
[TBL] [Abstract][Full Text] [Related]
33. Implementing type I & type II error spending for two-sided group sequential designs.
Rudser KD; Emerson SS
Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
[TBL] [Abstract][Full Text] [Related]
34. Sequentially testing for a gene-drug interaction in a genomewide analysis.
Kelly P; Zhou Y; Whitehead J; Stallard N; Bowman C
Stat Med; 2008 May; 27(11):2022-34. PubMed ID: 17979181
[TBL] [Abstract][Full Text] [Related]
35. Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials.
Lai TL; Shih MC; Zhu G
Stat Med; 2006 Apr; 25(7):1149-67. PubMed ID: 16189814
[TBL] [Abstract][Full Text] [Related]
36. Adjusted significance levels for subgroup analyses in clinical trials.
Spiessens B; Debois M
Contemp Clin Trials; 2010 Nov; 31(6):647-56. PubMed ID: 20832503
[TBL] [Abstract][Full Text] [Related]
37. A simple stopping rule for declaring treatment ineffectiveness in clinical trials.
Enas GG; Offen WW
J Biopharm Stat; 1993 Mar; 3(1):13-22. PubMed ID: 8485534
[TBL] [Abstract][Full Text] [Related]
38. Efficient group sequential designs when there are several effect sizes under consideration.
Jennison C; Turnbull BW
Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
[TBL] [Abstract][Full Text] [Related]
39. Design of adaptive two-stage double-arm clinical trials for dichotomous variables.
Jiang Z; Xue F; Li C; Wang L; Cai H; Zhang C; Xia J
Contemp Clin Trials; 2010 May; 31(3):242-50. PubMed ID: 20172053
[TBL] [Abstract][Full Text] [Related]
40. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
